The DNA-encoded libraries platforms and services market is projected to be reach USD 4 billion by 2030, growing at an annualized rate of 17%, claims Roots Analysis

Published: January 2020

Using DNA to develop encoded libraries of pharmacological leads has enabled medical research community to assemble and maintain large collections of compounds in singular reaction tubes, capturing the attention of small and big pharma players

Roots Analysis has announced the addition of DNA-Encoded Libraries: Platforms and Services Market, 2020-2030” report to its list of offerings.

Over time, a variety of methods have been developed and implemented for the synthesis of DNA-encoded molecular libraries. The availability of such cost-effective screening technologies has disrupted the pharmacological lead discovery process. In fact, it has been demonstrated to significantly increase drug discovery throughput, compared to conventional technologies / methods.

To order this report, which features 40+ figures and 45+ tables, please visit this link

Key Market Insights 

Close to 30 DNA-encoded libraries are currently available / under development
Of these, over 20 libraries are designed for discovery of small molecule drugs, while others are presently suited for macrocycle leads. Presently, majority of these libraries (27%) contain more than 90 billion molecules and are primarily synthesized through the DNA-conjugate method (using the split-and-pool approach).

More than 50% of the firms offering DNA-encoded libraries are small-sized initiatives
This is followed by mid-sized and very large players, which capture 40% of the overall share; examples include (in alphabetical order, no selection criteria) ComInnex, Edelris, Nurix Therapeutics, Pharmaron and WuXi AppTec.

Europe is currently considered a hub for the synthesis and use of DNA-encoded libraries
We identified around 30 players that claimed to be engaged in the development of DNA-encoded libraries in this region. Prominent countries, where companies working on encoded molecular libraries are based include (in decreasing order of number of players) the US, China, Denmark, Switzerland, and Hungary.

Partnership activity within this domain has grown at an annualized rate of over 25%, between 2016 and 2018
In fact, around 60% of the reported deals were established post 2016; it is worth highlighting that the maximum number of partnerships were observed in 2017. Majority of these agreements were observed to be research agreements, representing over 60% of the total number of deals.

~60% of the revenues generated by DNA encoded library providers are estimated to be from milestone payments
By 2030, the market is expected to witness significant growth as the demand for novel molecules continues to increase. As a result, ongoing efforts and anticipated drug discovery initiatives are likely to translate into opportunities for companies offering DNA-encoded libraries.

To request a sample copy / brochure of this report, please visit this link   

Key Questions Answered
  • What is the role of DNA-encoded libraries in drug discovery?
  • What is the likely cost saving opportunity associated with the use of DNA-encoded libraries?
  • What are the prevalent trends and future opportunity areas within the DNA-encoded libraries market?
  • Who are the key service providers for DNA-encoded libraries?
  • What are the various initiatives undertaken by the big pharma players engaged in this domain?
  • What kind of partnership models are commonly adopted by stakeholders in this industry?
  • What are the key biological targets against which small molecule hits are being developed using DNA-encoded libraries?
  • How is the current and future market opportunity (from library licensing deals) likely to be distributed across important market segments?

The report features inputs from eminent industry stakeholders, according to whom DNA-encoded libraries have emerged as a powerful molecular screening tool for the discovery of pharmacological leads, even against biological targets that were previously considered undruggable. The report includes detailed transcripts of the discussions held with industry experts.

The research highlights the initiatives / detailed profiles of key players (listed below), featuring an overview of the company, service portfolio, a description of DNA-encoded libraries offered and an informed future outlook.

  • Amgen
  • AstraZeneca
  • DyNAbind
  • GSK
  • HitGen
  • Novartis
  • Pfizer
  • Roche
  • Vipergen
  • X-Chem

For additional details, please visit or email

You may also be interested in the following titles: 

  1. Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030
  2. Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms
  3. Genome Editing Services Market-Focus on CRISPR 2019-2030

Gaurav Chaudhary
+1 (415) 800 3415

+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry